{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T23:47:01Z","timestamp":1785887221580,"version":"3.56.0"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T00:00:00Z","timestamp":1774483200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005743","name":"Universit\u00e0 Cattolica del Sacro Cuore","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005743","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100032745","name":"Gilead Sciences Italia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100032745","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journalofliquidbiopsy.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Liquid Biopsy"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.jlb.2026.100463","type":"journal-article","created":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T04:10:07Z","timestamp":1774584607000},"page":"100463","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Cancer in a drop: Liquid biopsy highlights from the San Antonio Breast Cancer Symposium (SABCS) 2025"],"prefix":"10.1016","volume":"12","author":[{"given":"Eleonora","family":"Nicol\u00f2","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos","family":"Venetis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enes","family":"Erul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pasquale","family":"Pisapia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-3363-8512","authenticated-orcid":false,"given":"Letizia","family":"Pontolillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"Reduzzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jlb.2026.100463_bib1","series-title":"San Antonio Breast Cancer Symposium (SABCS)","article-title":"Deep proteomics and AI classifier for early breast cancer detection. PD5-03","author":"Drake","year":"2025"},{"key":"10.1016\/j.jlb.2026.100463_bib2","series-title":"San Antonio Breast Cancer Symposium (SABCS)","article-title":"Circulating determinants of response to immunotherapy in triple negative breast cancer (TNBC). PD7-01","author":"Stabellini","year":"2025"},{"key":"10.1016\/j.jlb.2026.100463_bib3","series-title":"San Antonio Breast Cancer Symposium (SABCS)","article-title":"Circulating immune correlates of pathological response to neoadjuvant pembrolizumab plus chemotherapy in High-risk, early-stage triple-negative breast cancer. PD7-03","author":"Yam","year":"2025"},{"key":"10.1016\/j.jlb.2026.100463_bib4","series-title":"San Antonio Breast Cancer Symposium (SABCS)","article-title":"Neo-n (neon): three-year event-free survival and ultrasensitive ctDNA dynamics in early triple-negative breast cancer treated with neoadjuvant carboplatin\/paclitaxel and nivolumab. PD7-10","author":"Loi","year":"2025"},{"key":"10.1016\/j.jlb.2026.100463_bib5","series-title":"San Antonio Breast Cancer Symposium (SABCS)","author":"Balic","year":"2025"},{"key":"10.1016\/j.jlb.2026.100463_bib6","series-title":"San Antonio Breast Cancer Symposium (SABCS)","article-title":"Tissue-free circulating tumour DNA detection in patients with early triple negative breast cancer from the c-TRAK-TN trial. RF3-05","author":"Cunningham","year":"2025"},{"key":"10.1016\/j.jlb.2026.100463_bib7","series-title":"San Antonio Breast Cancer Symposium (SABCS)","article-title":"Circulating tumor DNA (ctDNA) in human epidermal growth factor receptor 2-positive (HER2[+]) Early Breast Cancer (EBC): translational analysis of PHERGain neoadjuvant tailored treatment study. GS1-06","author":"Llombart-Cussac","year":"2025"},{"key":"10.1016\/j.jlb.2026.100463_bib8","series-title":"San Antonio Breast Cancer Symposium (SABCS)","article-title":"Tumor-informed circulating tumor DNA analysis to assess molecular residual disease for prognosis and prediction of benefit from palbociclib in the PALLAS trial. RF3-04","author":"Parsons","year":"2025"},{"key":"10.1016\/j.jlb.2026.100463_bib9","series-title":"San Antonio Breast Cancer Symposium (SABCS)","article-title":"5-year outcomes and ctDNA findings in the CLEVER trial targeting disseminated dormant tumor cells. PD5-02","author":"DeMichele","year":"2025"},{"key":"10.1016\/j.jlb.2026.100463_bib10","doi-asserted-by":"crossref","first-page":"3464","DOI":"10.1038\/s41591-025-03877-3","article-title":"Targeting dormant tumor cells to prevent recurrent breast cancer: a randomized phase 2 trial","volume":"31","author":"DeMichele","year":"2025","journal-title":"Nat Med"},{"key":"10.1016\/j.jlb.2026.100463_bib11","series-title":"San Antonio Breast Cancer Symposium (SABCS)","article-title":"Personalized circulating tumor DNA (ctDNA) testing, intervention, and temporal dynamics in ER+\/HER2\u2013 early-stage breast cancer (LEADER). PD5-01","author":"Medford","year":"2025"},{"key":"10.1016\/j.jlb.2026.100463_bib12","series-title":"San Antonio Breast Cancer Symposium (SABCS)","article-title":"Impact of circulating tumor DNA (ctDNA) surveillance on quality of life (QoL) for patients with early-stage breast cancer (EBC): prospective I-SURV study. PD5-05","author":"Cheng","year":"2025"},{"key":"10.1016\/j.jlb.2026.100463_bib13","series-title":"San Antonio Breast Cancer Symposium (SABCS)","article-title":"Prospective analysis of circulating tumor cell clearance and dynamics with adjuvant radiotherapy in locally advanced breast cancer. PD5-07","author":"Woodward","year":"2025"},{"key":"10.1016\/j.jlb.2026.100463_bib14","series-title":"San Antonio Breast Cancer Symposium (SABCS)","article-title":"Circulating tumour DNA (ctDNA) dynamics from patients with ER+, HER2- advanced breast cancer in the phase 3 EMBER-3 trial. PD5-08","author":"Bidard","year":"2025"},{"key":"10.1016\/j.jlb.2026.100463_bib15","series-title":"San Antonio Breast Cancer Symposium (SABCS)","author":"Bidard","year":"2025"},{"key":"10.1016\/j.jlb.2026.100463_bib16","series-title":"San Antonio Breast Cancer Symposium (SABCS)","article-title":"Capivasertib plus fulvestrant in hormone receptor-positive (HR+) advanced breast cancer (ABC): exploratory ctDNA analyses from the Phase 3 CAPItello-291 trial. RF7-05","author":"Turner","year":"2025"},{"key":"10.1016\/j.jlb.2026.100463_bib17","series-title":"San Antonio Breast Cancer Symposium (SABCS)","article-title":"Mechanisms of resistance to capivasertib in combination with CDK4\/6 inhibitor (CDK4\/6i) plus fulvestrant in patients with HR+\/HER2\u2212 advanced breast cancer (ABC): exploratory analysis from the Phase 1b CAPItello-292 study. RF4-04","author":"Raja Sudhan","year":"2025"},{"key":"10.1016\/j.jlb.2026.100463_bib18","series-title":"San Antonio Breast Cancer Symposium (SABCS)","article-title":"Pooled analysis of patients treated with 1st-line ribociclib + endocrine therapy in the MONALEESA studies: long-term progression-free survival. PD5-10","author":"Razavi","year":"2025"},{"key":"10.1016\/j.jlb.2026.100463_bib19","series-title":"San Antonio Breast Cancer Symposium (SABCS)","article-title":"Molecular features of response to palbociclib + fulvestrant \u00b1 inavolisib in HR+, HER2-, PIK3CA-mutated advanced breast cancer as assessed from baseline ctDNA in the pivotal Phase 3 INAVO120 trial. PD5-09","author":"Turner","year":"2025"},{"key":"10.1016\/j.jlb.2026.100463_bib20","series-title":"San Antonio Breast Cancer Symposium (SABCS)","article-title":"Ultrasensitive ctDNA tracking predicts exceptional response in HER2+ metastatic breast cancer. PS5-11","author":"Morganti","year":"2025"},{"key":"10.1016\/j.jlb.2026.100463_bib21","series-title":"San Antonio Breast Cancer Symposium (SABCS)","article-title":"Comprehensive genomic landscape of invasive lobular carcinoma reveals distinct molecular subtypes. PD9-01","author":"Lee","year":"2025"},{"key":"10.1016\/j.jlb.2026.100463_bib22","series-title":"San Antonio Breast Cancer Symposium (SABCS)","article-title":"Comprehensive genomic profiling and clinically targetable mutations of metastatic invasive lobular and no special type breast cancer. PD9-03","author":"Maynard","year":"2025"},{"key":"10.1016\/j.jlb.2026.100463_bib23","series-title":"San Antonio Breast Cancer Symposium (SABCS)","article-title":"Detecting subtype switching in metastatic breast cancer with circulating tumor DNA methylation profiling. PD2-08","author":"Pasha","year":"2025"},{"key":"10.1016\/j.jlb.2026.100463_bib24","series-title":"San Antonio Breast Cancer Symposium (SABCS)","article-title":"Convergent genomic evolution from early to lethal HR+\/HER2- metastatic breast cancer. PD2-09","author":"Priedigkeit","year":"2025"}],"container-title":["The Journal of Liquid Biopsy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950195426000093?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950195426000093?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T23:07:02Z","timestamp":1785884822000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2950195426000093"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":24,"alternative-id":["S2950195426000093"],"URL":"https:\/\/doi.org\/10.1016\/j.jlb.2026.100463","relation":{},"ISSN":["2950-1954"],"issn-type":[{"value":"2950-1954","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cancer in a drop: Liquid biopsy highlights from the San Antonio Breast Cancer Symposium (SABCS) 2025","name":"articletitle","label":"Article Title"},{"value":"The Journal of Liquid Biopsy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jlb.2026.100463","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V. on behalf of The International Society of Liquid Biopsy.","name":"copyright","label":"Copyright"}],"article-number":"100463"}}